Navigation Links
Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
Date:9/15/2008

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, September 25, 2008, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2008, and the status of the Company's product development and marketing activities.

Corgenix invites all those interested in hearing management's discussion of the annual results to join the call by dialing:

US attendees: (800) 894-5910

International attendees: +1 785 424 1052

Conference code is: CORGENIX

A question-and-answer session will follow the presentation by Corgenix management.

A replay will be available for 30 days following the call by dialing (800) 374-0934 for US participants and +1 402 220 0680 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin non-responsiveness. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Corgenix Expands Scientific Advisory Board
2. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
3. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
4. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
5. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
6. Corgenix Signs Technology Licensing Agreement With Japanese Government
7. MannKind to Present at the UBS Global Life Sciences Conference
8. Insmed to Present at Biosimilars 2008 Conference
9. Modigene to Present at the UBS Global Life Sciences Conference
10. Vical to Present at UBS Global Life Sciences Conference
11. Stryker to Host Conference Call on October 16, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):